Salil Dutt Barrett

1 Introduction Splenectomy has historically been a treatment of choice for a wide range of benign and malignant diseases [1]. Benign indications include refractory infection, symptomatic splenomegaly, splenic infarct, disorders driving pathological haemolysis or thrombocytopaenia and compressive symptoms from large benign lesions such as splenic cysts, haemangiomas, or lymphangiomas.